Charles River Laboratories International, Inc. (NYSE:CRL) is Congress Asset Management Co. MA’s 10th Largest Position

Congress Asset Management Co. MA cut its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 10.3% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 534,335 shares of the medical research company’s stock after selling 61,615 shares during the quarter. Charles River Laboratories International accounts for 1.4% of Congress Asset Management Co. MA’s portfolio, making the stock its 10th largest position. Congress Asset Management Co. MA owned 1.06% of Charles River Laboratories International worth $154,866,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in CRL. Harbor Investment Advisory LLC purchased a new position in shares of Charles River Laboratories International in the first quarter valued at $29,000. Berman Capital Advisors LLC boosted its stake in shares of Charles River Laboratories International by 42.6% in the fourth quarter. Berman Capital Advisors LLC now owns 144 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 43 shares during the period. Huntington National Bank boosted its stake in shares of Charles River Laboratories International by 121.8% in the first quarter. Huntington National Bank now owns 122 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 67 shares during the period. Valeo Financial Advisors LLC purchased a new position in shares of Charles River Laboratories International in the first quarter valued at $35,000. Finally, Wealthcare Advisory Partners LLC purchased a new position in shares of Charles River Laboratories International in the first quarter valued at $35,000. Institutional investors and hedge funds own 92.30% of the company’s stock.

In other news, Director George Massaro sold 371 shares of the stock in a transaction that occurred on Tuesday, May 11th. The shares were sold at an average price of $320.06, for a total value of $118,742.26. Following the completion of the transaction, the director now directly owns 5,696 shares in the company, valued at $1,823,061.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Birgit Girshick sold 1,675 shares of Charles River Laboratories International stock in a transaction on Friday, February 19th. The shares were sold at an average price of $293.92, for a total value of $492,316.00. Following the transaction, the vice president now owns 31,680 shares in the company, valued at $9,311,385.60. The disclosure for this sale can be found here. In the last three months, insiders sold 95,909 shares of company stock valued at $28,602,310. Company insiders own 1.90% of the company’s stock.

Charles River Laboratories International stock opened at $329.07 on Monday. Charles River Laboratories International, Inc. has a 52-week low of $161.88 and a 52-week high of $349.13. The company has a quick ratio of 1.22, a current ratio of 1.45 and a debt-to-equity ratio of 1.04. The firm has a market capitalization of $16.54 billion, a price-to-earnings ratio of 54.85, a PEG ratio of 2.19 and a beta of 1.12. The firm has a 50-day moving average price of $316.59 and a two-hundred day moving average price of $274.38.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Monday, May 3rd. The medical research company reported $2.53 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.19 by $0.34. Charles River Laboratories International had a return on equity of 22.41% and a net margin of 10.68%. The business had revenue of $824.60 million during the quarter, compared to the consensus estimate of $798.52 million. During the same period in the previous year, the firm posted $1.84 earnings per share. The business’s revenue was up 16.6% on a year-over-year basis. Research analysts expect that Charles River Laboratories International, Inc. will post 7.87 earnings per share for the current year.

A number of research firms have commented on CRL. Truist increased their price objective on shares of Charles River Laboratories International from $256.00 to $324.00 in a research note on Thursday, February 18th. KeyCorp increased their price objective on shares of Charles River Laboratories International from $340.00 to $360.00 and gave the company an “overweight” rating in a research note on Friday. Morgan Stanley increased their price objective on shares of Charles River Laboratories International from $280.00 to $350.00 and gave the company an “overweight” rating in a research note on Thursday, February 25th. Credit Suisse Group increased their price objective on shares of Charles River Laboratories International from $259.00 to $301.00 and gave the company a “neutral” rating in a research note on Thursday, February 18th. Finally, Deutsche Bank Aktiengesellschaft increased their price objective on shares of Charles River Laboratories International from $334.00 to $354.00 and gave the company a “buy” rating in a research note on Wednesday, May 5th. Four research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Charles River Laboratories International presently has a consensus rating of “Buy” and an average target price of $299.00.

About Charles River Laboratories International

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Featured Story: Gap Up Stocks

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.